Leerink Partnrs has cut its Q3 2025 earnings estimate for Regeneron Pharmaceuticals, citing lowered expectations across the ...

The consumer privacy ombudsman in 23andMe’s sale of customers’ genetic data is defending his choice of counsel against ...

The franchise drug for autoimmune disorders such as dermatitis could face a challenger: A candidate from Apogee Therapeutics.

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) is one of the most undervalued large cap stocks to buy according to analysts.

Braun Stacey Associates cut its stake in Regeneron Pharmaceuticals by 4.5% during the first quarter, lowering its holdings to ...

Genetic testing company 23andMe can proceed with a $305 million sale to the company’s co-founder Anne Wojcicki after a U.S.

This was the stock's second consecutive day of losses.

Apogee Therapeutics Inc. plans to enter a crowded atopic dermatitis market with established drugs, such as Dupixent (dupilumab, Regeneron Pharmaceuticals Inc. and Sanofi SA) and Ebglyss ...

We may or may not be out of the woods, but focusing on the short-term performance of stocks is not the best strategy.

Regeneron Pharmaceuticals has received accelerated FDA approval for Lynozyfic, a new bispecific antibody treatment for adults with relapsed or refractory multiple myeloma who have undergone at least ...

Regeneron Pharmaceuticals, Inc. REGN obtained FDA approval for linvoseltamab-gcpt for the treatment of relapsed or refractory ...

Stay Informed On Tariff Changes, Macroeconomic Trends, And More.” — The Business Research Company LONDON, GREATER LONDON, UNITED KINGDOM, July 3, 2025 /EINPresswire.com/ -- What Does The Growth ...